Source-grounded facts extracted from Intellia Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Intellia Therapeutics, Inc. shareholders approved Non-binding advisory vote on compensation of named executive officers at the 2026-06-09 meeting.
“The stockholders of the Company approved, on a non-binding advisory basis, the compensation of our named executive officers.”
Intellia Therapeutics, Inc. shareholders approved Ratification of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-09 meeting.
“The stockholders of the Company ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.”
Intellia Therapeutics, Inc. shareholders approved Election of Class I Directors at the 2026-06-09 meeting.
“The stockholders of the Company elected each of Muna Bhanji, R.Ph., Brian Goff and Jesse Goodman, M.D., M.P.H., as a class I director, for a three-year term ending at the annual meeting of stockholders to be held in 2029 and until his or her successor has been duly elected and qualified or until his or her earlier resignation or removal.”
Intellia Therapeutics, Inc. reported the first quarter ended March 31, 2026 results: revenue $15.0 million. Guidance reaffirmed.
“commercial launch for HAE in the first half of 2027. This guidance excludes all potential commercial revenues from lonvo-z. • Collaboration Revenue : Collaboration revenue was $15.0 million for the first quarter of 2026, compared to $16.6 million for the first quarter of 2025. • R&D Expenses : Research and development (R&D) expenses were $80.7 million for the first”
Intellia Therapeutics, Inc. entered into Underwriting Agreement with Jefferies LLC, Goldman Sachs & Co. LLC, and Citigroup Global Markets Inc. valued at approximately $194.6 million (effective 2026-04-28).
“On April 28, 2026, Intellia Therapeutics, Inc. (the “Company” or “Intellia”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, Goldman Sachs & Co. LLC, and Citigroup Global Markets Inc. (the “Underwriters”), related to a public offering (the “Offering”) of 16,744,187 shares of common stock of the Company, par value $0.0001 per share (the “Common Stock”) at a price to the public of $10.75 per share.”
Intellia Therapeutics, Inc.: Board adopted Fourth Amended and Restated By-laws adding a cure period for deficiencies in shareholder notices and designating federal district courts as exclusive forum for federal securities law actions (effective 2026-04-07).
“On April 7, 2026, based on the recommendation of the nominating and corporate governance committee of the board of directors (the “Board”) of Intellia Therapeutics, Inc. (the “Company”), the Board adopted amendments to the Company’s Third Amended and Restated By-laws. Under the Fourth Amended and Restated By-laws, which are effective April 7, 2026 (the “Amended By-laws”), the Company added a provision allowing shareholders to cure any facially apparent deficiencies in a shareholder’s timely notice of a nomination or proposal, and requiring the Company to notify the shareholder of any facially apparent deficiencies in a timely notice. In addition, the Amended By-laws designate the federal district courts of the United States as the exclusive forum for resolving any complaint that asserts a cause of action arising under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, or the respective rules and regulations promulgated thereunder, unless the Com”
Intellia Therapeutics, Inc. amended Sales Agreement with Jefferies LLC valued at $1,035,316,650 (effective 2026-03-02).
“On March 2, 2026, the Company entered into an amendment to the Sales Agreement to increase the size of the at-the-market offering program from $750,000,000 to $1,035,316,650.”
Intellia Therapeutics, Inc.: Amended and restated bylaws to adopt majority vote standard in uncontested elections, implement proxy solicitation procedures consistent with Rule 14a-19, and make clarifying changes (effective 2025-04-03).
“On April 3, 2025, based on the recommendation of the nominating and corporate governance committee of the board of directors (the “Board”) of Intellia Therapeutics, Inc. (the “Company”), the Board adopted and approved the amendment and restatement of the Company’s Second Amended and Restated By-laws in their entirety, effective as of April 3, 2025.”
Intellia Therapeutics, Inc. announced a restructuring with charges of approximately $8 million (approximately 27%).
“On January 9, 2025, the Company announced the prioritization of its current and near-term clinical programs and a strategic restructuring to streamline its operations. These changes are expected to extend the Company’s cash runway into the first half of 2027. In connection with this portfolio prioritization and strategic restructuring, the Company expects to implement a net reduction of its employee headcount by approximately 27% over 2025. The Company estimates that it will incur charges of approximately $8 million for severance and other employee termination-related costs, primarily in the first quarter of 2025.”
Birgit Schultes was appointed as Executive Vice President and Chief Scientific Officer at Intellia Therapeutics, Inc..
“Birgit Schultes, Ph.D. will become the Company’s Executive Vice President and CSO, effective as of January 13, 2025.”
Laura Sepp-Lorenzino changed role as Special Advisor to the Chief Executive Officer at Intellia Therapeutics, Inc..
“effective January 13, 2025, Dr. Sepp-Lorenzino will become Special Advisor to the Chief Executive Officer of the Company.”
Laura Sepp-Lorenzino departed as Executive Vice President and Chief Scientific Officer at Intellia Therapeutics, Inc..
“Laura Sepp-Lorenzino, Ph.D., the Company’s Executive Vice President and Chief Scientific Officer (“CSO”), will retire from the Company and that her anticipated retirement date is December 31, 2025.”
Michael P. Dube was appointed as interim principal financial officer at Intellia Therapeutics, Inc..
“Michael P. Dube, the Company’s Chief Accounting Officer, will serve as the Company’s interim principal financial officer until the Start Date.”
Edward Dulac was appointed as Executive Vice President and Chief Financial Officer at Intellia Therapeutics, Inc..
“the Company announced the appointment, effective July 22, 2024 (“Start Date”), of Edward Dulac to serve as Executive Vice President and Chief Financial Officer (“CFO”), treasurer and principal financial officer of the Company.”
Glenn Goddard departed as Chief Financial Officer at Intellia Therapeutics, Inc..
“the Company also announced that Glenn Goddard, the Company’s current CFO, will step down effective June 30, 2024.”
Brian Goff was appointed as Class I Director at Intellia Therapeutics, Inc..
“On June 12, 2024, upon the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the “Board”) of Intellia Therapeutics, Inc. (the “Company”), the Board appointed Brian Goff, as a Class I director, effective as of June 13, 2024, with a term expiring at the 2026 annual meeting of stockholders.”
Intellia Therapeutics, Inc. reported financial results for first quarter ended March 31, 2024.
“On May 9, 2024, Intellia Therapeutics, Inc. announced its financial results and business updates for the quarter ended March 31, 2024.”
Michael P. Dube was appointed as principal accounting officer at Intellia Therapeutics, Inc..
“On April 10, 2024, Intellia Therapeutics, Inc. (the “Company” or “Intellia”) appointed Michael P. Dube, 46, as principal accounting officer of the Company.”
Intellia Therapeutics, Inc. terminated Factor IX Co-Development and Co-Funding Agreement with Regeneron Pharmaceuticals, Inc. (effective 2024-03-19).
“On March 19, 2024, Intellia Therapeutics, Inc. (the “Company” or “Intellia”) notified Regeneron Pharmaceuticals, Inc. (“Regeneron”) that the Company is opting out of its Factor IX Co-Development and Co-Funding Agreement (the “Co-Co Agreement”), which the Company and Regeneron entered into in May 2020.”
Intellia Therapeutics, Inc. amended Sales Agreement with Jefferies LLC valued at increase from $400,000,000 to $750,000,000 (effective 2024-02-23).
“On February 23, 2024, the Company entered into an amendment to the Sales Agreement to increase the size of the at-the-market offering program from $400,000,000 to $750,000,000.”
Intellia Therapeutics, Inc. reported financial results for the fourth quarter and year ended December 31, 2023.
“On February 22, 2024, Intellia Therapeutics, Inc. announced its financial results and business updates for the quarter and year ended December 31, 2023.”
Intellia Therapeutics, Inc. reported preliminary financial results for the fourth quarter and fiscal year ended December 31, 2023.
“Although it has not finalized its full financial results for the fourth quarter and fiscal year ended December 31, 2023, Intellia Therapeutics, Inc. (the “Company”) announced on January 4, 2024, that it expects to report that it had approximately $1.0 billion of cash, cash equivalents and marketable securities as of December 31, 2023.”
John F. Crowley resigned as Board of Directors at Intellia Therapeutics, Inc..
“On December 5, 2023, John F. Crowley notified Intellia Therapeutics, Inc. (the “Company”) of his intent to resign from the Board of Directors (the “Board”) of the Company and its committees, effective December 5, 2023.”
Intellia Therapeutics, Inc. reported financial results for the third quarter ended September 30, 2023.
“Intellia Therapeutics, Inc. announced its financial results and business updates for the quarter ended September 30, 2023.”
Intellia Therapeutics, Inc. reported financial results for the quarter ended June 30, 2023.
“On August 3, 2023, Intellia Therapeutics, Inc. announced its financial results and business updates for the quarter ended June 30, 2023.”
Intellia Therapeutics, Inc.: Increased authorized shares of common stock from 120,000,000 to 240,000,000 (effective 2023-06-14).
“On June 14, 2023, Intellia Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment (the “Amendment”) to the Company’s Second Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to increase the number of authorized shares of common stock from 120,000,000 to 240,000,000.”
Intellia Therapeutics, Inc. shareholders approved Amendment to Certificate of Incorporation to increase authorized shares from 120,000,000 to 240,000,000 at the 2023-06-14 meeting.
“The stockholders of the Company approved and adopted an amendment to the Company’s Second Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 120,000,000 to 240,000,000.”
Intellia Therapeutics, Inc. shareholders approved Advisory vote on compensation of named executive officers at the 2023-06-14 meeting.
“The stockholders of the Company approved, on an advisory basis, the compensation of the named executive officers.”
Intellia Therapeutics, Inc. shareholders approved Ratification of Deloitte & Touche LLP as independent registered public accounting firm at the 2023-06-14 meeting.
“The stockholders of the Company ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.”
Intellia Therapeutics, Inc. shareholders approved Election of Class I Directors at the 2023-06-14 meeting.
“The stockholders of the Company elected Muna Bhanji, R.Ph., John F. Crowley and Jesse Goodman, M.D., M.P.H. as class I directors, for a three-year term ending at the annual meeting of stockholders to be held in 2026 and until his or her successor has been duly elected and qualified or until his or her earlier resignation or removal.”
Jean-François Formela resigned as Director at Intellia Therapeutics, Inc..
“On June 5, 2023, Jean-François Formela notified Intellia Therapeutics, Inc. (the “Company”) of his intent to resign from the Board of Directors (the “Board”) of the Company and its committees, effective June 15, 2023.”
Intellia Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2023.
“CAMBRIDGE, Mass., May 4, 2023 – Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today reported operational highlights and financial results for the first quarter ended March 31, 2023.”
Bill Chase was appointed as Class III Director at Intellia Therapeutics, Inc..
“the Board appointed Bill Chase, M.B.A., as a Class III director, with a term expiring at the 2025 annual meeting of stockholders.”
Caroline Dorsa resigned as Director at Intellia Therapeutics, Inc..
“On March 23, 2023, Caroline Dorsa notified Intellia Therapeutics, Inc. (the “Company”) of her intent to resign from the Board of Directors (the “Board”) of the Company and its committees, effective June 15, 2023.”
Intellia Therapeutics, Inc. reported financial results for quarter and year ended December 31, 2022.
“On February 23, 2023, Intellia Therapeutics, Inc. announced its financial results and business updates for the quarter and year ended December 31, 2022.”
Intellia Therapeutics, Inc. reported preliminary financial results for the fourth quarter and fiscal year ended December 31, 2022.
“Although it has not finalized its full financial results for the fourth quarter and fiscal year ended December 31, 2022, Intellia Therapeutics, Inc. (the “Company”) announced on January 5, 2023, that it expects to report that it had approximately $1.3 billion of cash, cash equivalents and marketable securities as of December 31, 2022.”
Intellia Therapeutics, Inc. entered into Underwriting Agreement with Goldman Sachs & Co. LLC valued at approximately $293.5 million (effective 2022-11-30).
“On November 30, 2022, Intellia Therapeutics, Inc. (the “Company” or “Intellia”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Goldman Sachs & Co. LLC (the “Underwriter”), related to a public offering (the “Offering”) of 6,550,219 shares of common stock of the Company, par value $0.0001 per share (the “Common Stock”) at a price to the public of $45.80 per share.”
Intellia Therapeutics, Inc. reported financial results for third quarter ended September 30, 2022.
“On November 3, 2022, Intellia Therapeutics, Inc. announced its financial results and business updates for the quarter ended September 30, 2022.”
Muna Bhanji was appointed as Director at Intellia Therapeutics, Inc..
“On April 28, 2022, upon the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the “Board”) of Intellia Therapeutics, Inc. (the “Company”), the Board appointed Muna Bhanji, as a Class I director”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.